ORALAIR 300 IR Sublingual Tablets

2. What you need to know before taking ORALAIR

Do not take ORALAIR if:

• You are allergic to any of the other components of this medication (listed in section 6);
• You have severe or unstable asthma or have suffered from severe asthma exacerbations in the last 3 months;
• Your forced expiratory volume in one second (FEV1) is less than 80% as assessed by your doctor;
• You have a disease that affects your immune system, are taking medications that suppress the immune system, or have cancer;
• You have mouth ulcers or oral infections. Your doctor may recommend delaying the start of treatment or interrupting it until your mouth has healed.

Do not start taking ORALAIR if you are pregnant.

Warnings and precautions

Consult your doctor or pharmacist before starting to take ORALAIR if:

• You experience severe allergic symptoms, such as difficulty swallowing or breathing, changes in your voice, hypotension (low blood pressure), or a sensation of a lump in the throat. Interrupt treatment and contact your doctor immediately.
• You have previously had severe allergic reactions to a medication containing allergen extracts.
• Your asthma symptoms worsen more than usual. Interrupt treatment and contact your doctor immediately.
• You have a cardiovascular disease.
• You are taking a beta-blocker (a class of medications commonly prescribed for heart conditions and high blood pressure, but also present in some eye drops and ointments).
• You are being treated for depression with tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs), or for Parkinson's disease with catechol-O-methyltransferase (COMT) inhibitors.
• You need to undergo oral surgery or a dental extraction, you should interrupt treatment with ORALAIR until you are fully healed.
• You persistently experience heartburn or difficulty swallowing. You should contact your doctor.
• You have an autoimmune disease in remission.

Tell your doctor about:

• Any recent illness you may have had,
• Family or personal history of any disease that could affect your immune system,
• If your allergic disease has recently worsened.

If you take medications to control and/or relieve asthma, do not stop asthma treatment without your doctor's advice, as this may worsen asthma symptoms. If you have asthma and a respiratory infection, you should postpone the start of treatment with ORALAIR until the infection has resolved.

You may expect some localized allergic reactions, from mild to moderate, during treatment. If these reactions are severe, talk to your doctor to see if you need any anti-allergic medication such as antihistamines.

Children and adolescents

ORALAIR is used for the treatment of grass pollen allergy with or without conjunctivitis in adolescents and children from 5 years of age. ORALAIR is not indicated for use in children under 5 years of age.

Other medications and ORALAIR

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications, including those without a prescription.

Especially inform your doctor if you are taking certain antidepressants (tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs).

If you are taking other medications for allergies, such as antihistamines, medications for asthma relief, or steroids, or medications that block a substance called immunoglobulin E (IgE), such as omalizumab, talk to your doctor if you should continue taking them. If you stop taking those allergy medications, you may experience more side effects during treatment with ORALAIR. Symptomatic treatment (e.g., antihistamines and/or nasal corticosteroids) can be used along with ORALAIR.

Consult your doctor or pharmacist before taking Oralair: if you are taking a beta-blocker (i.e., a type of medication commonly prescribed for heart disorders and high blood pressure, and also present in some eye drops and ointments), as this medication may reduce the effectiveness of adrenaline used to treat severe systemic reactions.

Taking ORALAIR with food and drinks

Do not eat or drink during the 5 minutes following the intake of this medication.

Pregnancy and breastfeeding

Pregnancy

If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

There is no experience with the use of ORALAIR during pregnancy. Therefore, you should not start immunotherapy if you are pregnant. If you become pregnant while taking this medication, consult your doctor about whether it is appropriate to continue treatment.

Breastfeeding

If you are breastfeeding, consult your doctor or pharmacist before using this medication.

You should not start immunotherapy if you are breastfeeding.

There is no experience with the use of ORALAIR during breastfeeding. No effects on breastfed infants are expected during treatment. If you wish to breastfeed your baby while being treated, consult your doctor to see if it is appropriate for you to continue treatment.

Driving and using machines

No effects of ORALAIR on the ability to drive or use machines have been observed

ORALAIR contains lactose

If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.

ORALAIR contains sodium

This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free).

3. How to take ORALAIR

Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

ORALAIR is prescribed by doctors with adequate training and experience in the treatment of allergies. In the prescription for children, the doctor has adequate experience in the treatment of children.

You are advised to take the first tablet under medical supervision. This will give you the opportunity to talk to your doctor about possible adverse reactions.

Dosage

The treatment consists of an initiation phase (including a dose increase over three days) and a maintenance treatment phase. ORALAIR 300 IR is indicated only for the maintenance phase.

Take one 300 IR tablet once a day.

Method of administration

The first dose of ORALAIR must be taken under medical supervision. You must remain under medical observation for at least half an hour after taking the first dose. This is a precaution to monitor your sensitivity to the medication. It will also give you the opportunity to talk to your doctor about possible side effects.

Keep the tablet under your tongue until it is completely dissolved (at least one minute) before swallowing. It is recommended to take the tablet during the day, with an empty mouth. Do not eat or drink for at least 5 minutes.

Duration of treatment

Take these tablets, as prescribed by your doctor, until the end of the treatment period. Start treatment approximately 4 months before the start of the pollen season and continue until the end of it.

There is no experience with ORALAIR in patients over 65 years of age.

Use in children and adolescents

There is no experience with ORALAIR in children under 5 years of age.

There is no experience with ORALAIR for more than one pollen season in children.

The dose in adolescents and children from 5 years of age is the same as in adults.

If you take more ORALAIR than you should

If you take more ORALAIR than you should, you may experience allergic symptoms, even localized symptoms in the mouth and throat. If you experience severe symptoms, consult your doctor immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take ORALAIR

Do not take a double dose to make up for forgotten doses.

If you have interrupted treatment with ORALAIR for less than one week, you can resume treatment with the same dose.

If you interrupted treatment for more than 7 days, consult your doctor on how to resume your treatment.

If you stop taking ORALAIR

If you do not complete treatment with ORALAIR, you may not obtain a continued benefit from treatment.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone experiences them.

During treatment with ORALAIR, you will be exposed to substances that can cause local reactions at the site of application and/or symptoms that can affect the whole body. Local reactions at the site of application, such as itching in the mouth and irritation in the throat, can be expected. These reactions usually occur at the start of therapy, are transient, and generally decrease over time.

Stop taking ORALAIR and contact your doctor or hospital immediately if you experience any of the following symptoms:

• Rapid swelling of the face, mouth, throat, or skin.
• Difficulty swallowing
• Difficulty breathing
• Voice changes
• Hypotension (low blood pressure)
• Sensation of fullness in the throat (like swelling)
• Urticaria or itching of the skin

Treatment should only be resumed following the instructions of a doctor.

Other possible side effects

Very common(may affect more than 1 in 10 people):

• Itching in the mouth
• Irritation of the throat
• Headache

Common (may affect up to 1 in 10 people):

• Inflammation in the eyes, itching in the eyes, or tearing
• Itching in the ears
• Rhinitis (nasal congestion, nasal discharge, itching in the nose, sneezing, nasal discomfort), sinus congestion
• Swelling or itching of the lips or tongue, pain in the tongue
• Disorders in the mouth (such as dryness, tingling, numbness, inflammation, pain, blisters, or swelling)
• Disorders in the throat (such as dryness, discomfort, pain, blisters, or swelling), hoarseness, difficulty swallowing
• Inflammation of the mouth, nose, and throat
• Asthma, difficulty breathing
• Cough
• Chest discomfort
• Heartburn, stomach upset, stomach pain, diarrhea, vomiting, nausea
• Persistent skin disease characterized by dryness, redness, and itching, urticaria, itching

Uncommon (may affect up to 1 in 100 people):

• Swelling of the eyes, redness of the eyes, dryness in the eyes
• Ear infection, dizziness, ear discomfort
• Ulceration of the mouth or tongue, inflammation of the palate, inflammation of the gums, lips, or tongue
• Enlargement of the salivary glands, excessive saliva production
• Altered taste, belching
• Sensation of pressure in the throat, numbness of the throat, sensation of a foreign body in the throat
• Wheezing
• Allergic reactions that occur with inflammation of the face and throat, hypersensitivity
• Swollen lymph nodes
• Skin rash, acne, herpes, skin lesion after scratching
• Depression, fatigue, drowsiness
• Flu-like illness

Rare (may affect up to 1 in 1,000 people):

• Swelling of the face, flushing
• Anxiety
• Increased eosinophil count

Frequency not known (cannot be estimated from the available data):

Esophageal inflammation has also been reported.

The number of adverse effects reported in a clinical study in adults treated with ORALAIR during three consecutive grass pollen seasons decreased during the second and third year.

Adverse effects in children and adolescents

The following adverse effects were more frequent in children and adolescents who received ORALAIR than in adults: cough, inflammation of the nose and throat, oral edema (very common), oral allergy syndrome, lip inflammation, sensation of a lump in the throat, tongue inflammation, ear discomfort (common).

Additionally, the following adverse reactions were also reported in children and adolescents: bronchitis, tonsillitis (common), chest pain (uncommon).

Other adverse effects observed in adults, adolescents, and children(post-marketing experience, frequency unknown):

Worsening of asthma, systemic allergic reactions.

Reporting of side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of ORALAIR

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date stated on the packaging after "EXP" and on the blister pack after "EXP". The expiration date is the last day of the month indicated.

This medication does not require any special storage temperature.

Store in the original packaging to protect from moisture.

Medications should not be disposed of via wastewater or household waste. Place the packaging and any unused medication in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.

6. Package Contents and Additional Information

Composition of ORALAIR

• The active ingredient is an allergenic extract of grass pollen from: Dactyl ( Dactylis glomerataL.), sweet vernal grass ( Anthoxanthum odoratumL.), perennial ryegrass ( Lolium perenneL.), meadow grass ( Poa pratensisL.), and timothy grass ( Phleum pratenseL.). One sublingual tablet contains 300 IR.

The IR (index of reactivity) expresses the activity and is determined in sensitized patients through a skin sensitivity test.

• The other components are mannitol (E 421), microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate, and lactose monohydrate.

Appearance of the Product and Package Contents

The tablets are white to beige in color, slightly speckled, and engraved with "300" on both sides.

A blister pack with 30 sublingual tablets of 300 IR.

The tablets are supplied in blisters (Alu/Alu) composed of a film (polyamide/aluminum/polyvinyl chloride).

Package sizes: 30 and 90 sublingual tablets.

Only some package sizes may be marketed.

Marketing Authorization Holder and Manufacturer

STALLERGENES

6 rue Alexis de Tocqueville

92160 ANTONY

France

Tel.: 00 33 1 55 59 20 00

Fax: 00 33 1 55 59 21 68

For further information about this medicinal product, please contact the local representative of the marketing authorization holder:

Stallergenes Ibérica S.A.

Llacuna, 22 – 2º 1ª

08005 BARCELONA

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Austria Oralair 300 IR Sublingualtabletten

Belgium, Estonia, Germany, Ireland, Italy, Latvia, Luxembourg, Netherlands, Poland, Portugal, Romania, Slovakia

Oralair 300 IR

Bulgaria, Czech Republic ORALAIR 300 IR

Croatia Oralair 300 IR sublingvalne tablete

Denmark, Finland, Norway, Sweden Aitgrys

France Oralair 300 IR, comprimé sublingual

Hungary Oralair 300 IR, nyelvalatti tabletta

Lithuania ORALAIR 300 IR poliežuvines tabletes

Slovenia Oralair 300 IR podjezicne tablete

Spain ORALAIR 300 IR comprimidos sublinguales

Date of the last revision of this leaflet: December 2023

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/